These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35100303)

  • 21. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N; Massare MJ; Tian JH; Guebre-Xabier M; Lu H; Zhou H; Maynard E; Scott D; Ellingsworth L; Glenn G; Smith G
    Vaccine; 2019 Sep; 37(41):6112-6124. PubMed ID: 31416644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention.
    Magro M; Mas V; Chappell K; Vázquez M; Cano O; Luque D; Terrón MC; Melero JA; Palomo C
    Proc Natl Acad Sci U S A; 2012 Feb; 109(8):3089-94. PubMed ID: 22323598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal Delivery of Recombinant Vesicular Stomatitis Virus Vectors Expressing Envelope Proteins of Respiratory Syncytial Virus Induces Protective Immunity in Cotton Rats.
    Binjawadagi B; Ma Y; Binjawadagi R; Brakel K; Harder O; Peeples M; Li J; Niewiesk S
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33408176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase 1 Safety and Immunogenicity Study of a Respiratory Syncytial Virus Vaccine With an Adenovirus 26 Vector Encoding Prefusion F (Ad26.RSV.preF) in Adults Aged ≥60 Years.
    Williams K; Bastian AR; Feldman RA; Omoruyi E; de Paepe E; Hendriks J; van Zeeburg H; Godeaux O; Langedijk JPM; Schuitemaker H; Sadoff J; Callendret B
    J Infect Dis; 2020 Aug; 222(6):979-988. PubMed ID: 32320465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal immunization with HRSV prefusion F protein and CpG adjuvant elicits robust protective effects in mice.
    Ren H; Li H; Cao L; Wang Z; Zhou Y; Guo J; Zhang Y; Liu H; Xu W
    Vaccine; 2022 Nov; 40(47):6830-6838. PubMed ID: 36253219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
    Sarkar I; Garg R; van Drunen Littel-van den Hurk S
    Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response.
    Ma Y; Jiao YY; Yu YZ; Jiang N; Hua Y; Zhang XJ; Fu YH; Peng XL; Zheng YP; Anderson LJ; He JS
    Viruses; 2018 Jan; 10(1):. PubMed ID: 29342954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nasal immunization with RSV F and G protein fragments conjugated to an M cell-targeting ligand induces an enhanced immune response and protection against RSV infection.
    Khan IU; Huang J; Li X; Xie J; Zhu N
    Antiviral Res; 2018 Nov; 159():95-103. PubMed ID: 30290196
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S; Quan FS; Kwon Y; Sakamoto K; Kang SM; Compans RW; Moore ML
    Antiviral Res; 2014 Nov; 111():129-35. PubMed ID: 25239522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats.
    Widjojoatmodjo MN; Bogaert L; Meek B; Zahn R; Vellinga J; Custers J; Serroyen J; Radošević K; Schuitemaker H
    Vaccine; 2015 Oct; 33(41):5406-5414. PubMed ID: 26319741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu YH; He JS; Qiao W; Jiao YY; Hua Y; Zhang Y; Peng XL; Hong T
    Virol J; 2013 Jun; 10():183. PubMed ID: 23742026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA vaccine encoding central conserved region of G protein induces Th1 predominant immune response and protection from RSV infection in mice.
    Hua Y; Jiao YY; Ma Y; Peng XL; Fu YH; Zheng YP; Hong T; He JS
    Immunol Lett; 2016 Nov; 179():95-101. PubMed ID: 27688078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
    Falloon J; Ji F; Curtis C; Bart S; Sheldon E; Krieger D; Dubovsky F; Lambert S; Takas T; Villafana T; Esser MT
    Vaccine; 2016 May; 34(25):2847-54. PubMed ID: 27102821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protection against respiratory syncytial virus infection by DNA immunization.
    Li X; Sambhara S; Li CX; Ewasyshyn M; Parrington M; Caterini J; James O; Cates G; Du RP; Klein M
    J Exp Med; 1998 Aug; 188(4):681-8. PubMed ID: 9705950
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of inactivated split respiratory syncytial virus as a vaccine candidate and the effects of novel combination adjuvants.
    Lee Y; Ko EJ; Kim KH; Lee YT; Hwang HS; Jung YJ; Jeeva S; Kwon YM; Seong BL; Kang SM
    Antiviral Res; 2019 Aug; 168():100-108. PubMed ID: 31150678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant baculovirus-based vaccine expressing M2 protein induces protective CD8
    Lee JY; Chang J
    J Microbiol; 2017 Nov; 55(11):900-908. PubMed ID: 29076066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naked DNA immunization with full-length attachment gene of human respiratory syncytial virus induces safe and protective immune response.
    Hamad ME; Amer HM; Farrag MA; Osman AH; Almajhdi FN
    Acta Virol; 2018; 62(2):137-146. PubMed ID: 29895154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired immune response to vaccination against infection with human respiratory syncytial virus at advanced age.
    Guichelaar T; Hoeboer J; Widjojoatmodjo MN; Reemers SS; van Els CA; Otten R; van Remmerden Y; Boes J; Luytjes W
    J Virol; 2014 Sep; 88(17):9744-50. PubMed ID: 24920795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.